Odnass Pty Ltd

Redifining Early Cancer Detection.
At Odnass, we believe that early detection saves lives. Our mission is simple yet ambitious: make life-saving cancer screening accessible, affordable, and accurate worldwide.

We are pioneering a breakthrough blood test designed to detect multiple cancers at their earliest, pre-symptomatic stage. Unlike existing liquid biopsies, the Odnass system directly analyses cell-free DNA (cfDNA) in plasma, using a proprietary protocol optimised for sensitivity, reproducibility, and cost-efficiency.

What sets us apart?
🔹 Direct cfDNA Detection â A simplified, kit-free protocol that reduces complexity and cost while enabling robust detection of cancer signals.
🔹 AI-Driven Predictive Modelling â Deep Machine Learning (DML) and Graph Neural Networks (GNN) integrate diverse biological and clinical factors, boosting predictive accuracy, reducing bias, and improving generalizability.
🔹 Blockchain Integration â Ensuring patient trust through immutable, transparent, and secure handling of sensitive health data.
🔹 Global Accessibility â Designed to be low-cost, scalable, and deployable in both developed and underserved healthcare systems.

Our intended use spans population-wide early cancer screening, targeted monitoring of high-risk individuals, occupational and environmental exposure testing, and integration with traditional screening programs.

With our provisional patent filed in July 2025, Odnass has entered the Proof-of-Concept phase, advancing with a capital-efficient strategy: validate the platform, strengthen IP, and position for acquisition by a Tier 1 MedTech partner.

🌍 Our vision: A world where cancer is detected early, treatment is more effective, and survival is dramatically improved.

📩 For collaboration or investment opportunities, contact:
velimir.p@odnass.com | admin@odnass.com

280 Bannister Rd, Unit 6, Canning Vale, Western Australia 6155, AU